Table of Contents Author Guidelines Submit a Manuscript
Emergency Medicine International
Volume 2016 (2016), Article ID 1781684, 13 pages
http://dx.doi.org/10.1155/2016/1781684
Review Article

Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians

1Section of Emergency Medicine, Baylor College of Medicine, Ben Taub General Hospital, 1504 Taub Loop, Houston, TX 77030, USA
2Department of Emergency Medicine, Stony Brook School of Medicine, University Medical Center L4, 100 Nicolls Road, Stony Brook, NY 11794-8350, USA

Received 8 January 2016; Revised 11 March 2016; Accepted 29 March 2016

Academic Editor: Chak W. Kam

Copyright © 2016 W. Frank Peacock et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. J. Caro, “An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation,” American Journal of Managed Care, vol. 10, no. 14, pp. S451–S461, 2004. View at Google Scholar · View at Scopus
  2. J. A. Heit, T. M. Petterson, S. A. Farmer, K. R. Balley, and L. J. Melton III, “Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 35-year population-based study,” ASH Annual Meeting Abstracts, vol. 108, p. 1488, 2006. View at Google Scholar
  3. M. D. Silverstein, J. A. Heit, D. N. Mohr, T. M. Petterson, W. M. O'Fallon, and L. J. Melton III, “Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study,” Archives of Internal Medicine, vol. 158, no. 6, pp. 585–593, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. P. P. Dobesh, “Economic burden of venous thromboembolism in hospitalized patients,” Pharmacotherapy, vol. 29, no. 8, pp. 943–953, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. C. J. Mercaldi, M. Ciarametaro, B. Hahn et al., “Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation,” Stroke, vol. 42, no. 1, pp. 112–118, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Kearon, E. A. Akl, A. J. Comerota et al., “Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines,” Chest, vol. 141, no. 2, pp. e419S–e494S, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Stellbrink, U. Nixdorff, T. Hofmann et al., “Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial,” Circulation, vol. 109, no. 8, pp. 997–1003, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. S. V. Rao and E. M. Ohman, “Anticoagulant therapy for percutaneous coronary intervention,” Circulation: Cardiovascular Interventions, vol. 3, no. 1, pp. 80–88, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Martel, J. Lee, and P. S. Wells, “Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis,” Blood, vol. 106, no. 8, pp. 2710–2715, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. W. Ageno, A. S. Gallus, A. Wittkowsky, M. Crowther, E. M. Hylek, and G. Palareti, “Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines,” Chest, vol. 141, no. 2, pp. e44S–e88S, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Ansell, J. Hirsh, E. Hylek et al., “Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),” Chest, vol. 133, pp. 160S–198S, 2008. View at Google Scholar
  12. L. Hamby, W. B. Weeks, and C. Malikowski, “Complications of warfarin therapy: causes, costs, and the role of the anticoagulation clinic,” Effective Clinical Practice, vol. 3, no. 4, pp. 179–184, 2000. View at Google Scholar · View at Scopus
  13. ELIQUIS®, Bristol-Myers Squibb Company, Princeton, NJ, USA; Pfizer Inc., New York, NY, USA, 2015, http://packageinserts.bms.com/pi/pi_eliquis.pdf.
  14. PRADAXA®, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Conn, USA, 2015, http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf.
  15. XARELTO, Janssen Pharmaceuticals, Titusville, NJ, USA, 2015, https://www.xarelto-us.com/shared/product/xarelto/prescribing-information.pdf.
  16. SAVAYSA, Daiichi Sankyo Inc, Parsippany, NJ, USA, 2015, http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf.
  17. Lixiana, Daiichi Sankyo Europe GmbH, Munich, Germany, 2015, https://www.medicines.org.uk/emc/PIL.30504.latest.pdf.
  18. Daiichi Sankyo, Daiichi Sankyo Launches LIXIANA(R) (edoxaban), a Direct Oral Factor Xa Inhibitor, in Japan for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery, Daiichi Sankyo, Tokyo, Japan, 2011, http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/005784.html.
  19. S. J. Connolly, M. D. Ezekowitz, S. Yusuf et al., “Dabigatran versus warfarin in patients with atrial fibrillation,” The New England Journal of Medicine, vol. 361, pp. 1139–1151, 2009. View at Google Scholar
  20. R. P. Giugliano, C. T. Ruff, E. Braunwald et al., “Edoxaban versus warfarin in patients with atrial fibrillation,” The New England Journal of Medicine, vol. 369, no. 22, pp. 2093–2104, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. C. B. Granger, J. H. Alexander, J. J. McMurray et al., “Apixaban versus warfarin in patients with atrial fibrillation,” The New England Journal of Medicine, vol. 365, pp. 981–992, 2011. View at Publisher · View at Google Scholar
  22. M. R. Patel, K. W. Mahaffey, J. Garg et al., “Rivaroxaban versus warfarin in nonvalvular atrial fibrillation,” The New England Journal of Medicine, vol. 365, no. 10, pp. 883–891, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. C. T. Ruff, R. P. Giugliano, E. Braunwald et al., “Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials,” The Lancet, vol. 383, no. 9921, pp. 955–962, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Chatterjee, P. Sardar, G. Biondi-Zoccai, and D. J. Kumbhani, “New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation,” JAMA Neurology, vol. 70, no. 12, pp. 1486–1490, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. N. Mackman, “The role of tissue factor and factor VIIa in hemostasis,” Anesthesia and Analgesia, vol. 108, no. 5, pp. 1447–1452, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Hirsh, V. Fuster, J. Ansell, and J. L. Halperin, “American Heart Association/American College of Cardiology Foundation guide to warfarin therapy,” Circulation, vol. 107, no. 12, pp. 1692–1711, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Desai, J. M. Kolb, J. I. Weitz, and J. Aisenberg, “Gastrointestinal bleeding with the new oral anticoagulants—defining the issues and the management strategies,” Thrombosis and Haemostasis, vol. 110, no. 2, pp. 205–212, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. M. S. Bathala, H. Masumoto, T. Oguma, L. He, C. Lowrie, and J. Mendell, “Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans,” Drug Metabolism and Disposition, vol. 40, no. 12, pp. 2250–2255, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Agnelli, H. R. Buller, A. Cohen et al., “Oral apixaban for the treatment of acute venous thromboembolism,” The New England Journal of Medicine, vol. 369, no. 9, pp. 799–808, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Bauersachs, S. D. Berkowitz, B. Brenner et al., “Oral rivaroxaban for symptomatic venous thromboembolism,” The New England Journal of Medicine, vol. 363, pp. 2499–2510, 2010. View at Google Scholar
  31. H. R. Buller, H. Decousus, M. A. Grosso et al., “Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism,” The New England Journal of Medicine, vol. 369, pp. 1406–1415, 2013. View at Publisher · View at Google Scholar
  32. H. R. Buller, M. H. Prins, A. W. Lensin et al., “Oral rivaroxaban for the treatment of symptomatic pulmonary embolism,” The New England Journal of Medicine, vol. 366, pp. 1287–1297, 2012. View at Publisher · View at Google Scholar
  33. S. Schulman, A. K. Kakkar, S. Z. Goldhaber et al., “Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis,” Circulation, vol. 129, no. 7, pp. 764–772, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. E. A. Nutescu, W. E. Dager, J. S. Kalus, J. J. Lewin, and M. D. Cipolle, “Management of bleeding and reversal strategies for oral anticoagulants: clinical practice considerations,” American Journal of Health-System Pharmacy, vol. 70, no. 21, pp. 1914–1929, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. PRAXBIND®, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Conn, USA, 2015, http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf.
  36. Thrombosis Canda, New/Noval Oral Anticoagulants (NOACs): Management of Bleeding, Thrombosis Canda, 2015, http://thrombosiscanada.ca/wp-content/uploads/2016/02/22_NOACs-Management-Bleeding_2016Jan12-FINAL.pdf.
  37. Bleeding—Management in Patients Taking Oral Anticoagulants, Wirral University Teaching Hospital (NHS), 2016, http://www.wuth.nhs.uk/media/984539/Bleeding-Management-in-patients-taking-oral-anticoagulants-4-July-13.pdf.
  38. D. M. Siegal, D. A. Garcia, and M. A. Crowther, “How I treat target-specific oral anticoagulant-associated bleeding,” Blood, vol. 123, no. 8, pp. 1152–1158, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. A. C. Spyropoulos, “Reimbursement strategies in an outpatient-based disease management program for the treatment of deep venous thrombosis in an integrated health care system,” Managed Care, vol. 8, supplement 1, pp. 14–20, 1999, http://www.managedcaremag.com/sites/default/files/supplements/9912_dvt_suppl/9912.dvt.pdf. View at Google Scholar
  40. J. D. Douketis, “Treatment of deep vein thrombosis: what factors determine appropriate treatment?” Canadian Family Physician, vol. 51, pp. 217–223, 2005. View at Google Scholar · View at Scopus
  41. J. I. Weitz and C. V. Pollack Jr., “Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants,” Thrombosis and Haemostasis, vol. 114, no. 6, pp. 1113–1126, 2015. View at Publisher · View at Google Scholar
  42. S. G. Goodman, D. M. Wojdyla, J. P. Piccini et al., “Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation),” Journal of the American College of Cardiology, vol. 63, no. 9, pp. 891–900, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Shoeb and M. C. Fang, “Assessing bleeding risk in patients taking anticoagulants,” Journal of Thrombosis and Thrombolysis, vol. 35, no. 3, pp. 312–319, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. J. A. Heit, “Venous thromboembolism: disease burden, outcomes and risk factors,” Journal of Thrombosis and Haemostasis, vol. 3, no. 8, pp. 1611–1617, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. V. Pengo, A. W. Lensing, M. H. Prins et al., “Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism,” The New England Journal of Medicine, vol. 350, no. 22, pp. 2257–2264, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. S. S. Adam, J. R. McDuffie, T. L. Ortel, and J. W. Williams Jr., “Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review,” Annals of Internal Medicine, vol. 157, no. 11, pp. 796–807, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. R. Pisters, D. A. Lane, R. Nieuwlaat, C. B. de Vos, H. J. Crijns, and G. Y. Lip, “A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey,” Chest, vol. 138, no. 5, pp. 1093–1100, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. S. G. Aller, J. Yu, A. Ward et al., “Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding,” Science, vol. 323, no. 5922, pp. 1718–1722, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. L. C. Quattrochi and P. S. Guzelian, “CYP3A regulation: from pharmacology to nuclear receptors,” Drug Metabolism and Disposition, vol. 29, no. 5, pp. 615–622, 2001. View at Google Scholar · View at Scopus
  50. C. Kearon, S. R. Kahn, G. Agnelli, S. Goldhaber, G. E. Raskob, and A. J. Comerota, “Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),” Chest, vol. 133, no. 6, pp. 454S–545S, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. K. Babilonia and T. Trujillo, “The role of prothrombin complex concentrates in reversal of target specific anticoagulants,” Thrombosis Journal, vol. 12, article 8, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. E. Gehrie and C. Tormey, “Novel oral anticoagulants: efficacy, laboratory measurement, and approaches to emergent reversal,” Archives of Pathology and Laboratory Medicine, vol. 139, no. 5, pp. 687–692, 2015. View at Publisher · View at Google Scholar · View at Scopus
  53. A. M. Winkler and C. A. Tormey, “Pathology consultation on monitoring direct thrombin inhibitors and overcoming their effects in bleeding patients,” The American Journal of Clinical Pathology, vol. 140, no. 5, pp. 610–622, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Curvers, D. van de Kerkhof, A. K. Stroobants, E.-J. van den Dool, and V. Scharnhorst, “Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful?” American Journal of Clinical Pathology, vol. 138, no. 4, pp. 551–558, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. D. D. Castellone and E. M. Van Cott, “Laboratory monitoring of new anticoagulants,” American Journal of Hematology, vol. 85, no. 3, pp. 185–187, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. R. C. Gosselin, D. M. Dwyre, and W. E. Dager, “Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay,” Annals of Pharmacotherapy, vol. 47, no. 12, pp. 1635–1640, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. W. Mueck, S. Schwers, and J. Stampfuss, “Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring,” Thrombosis Journal, vol. 11, article 10, 2013. View at Publisher · View at Google Scholar · View at Scopus
  58. M. A. Miyares and K. Davis, “Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient,” American Journal of Health-System Pharmacy, vol. 69, no. 17, pp. 1473–1484, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. T. Baglin, “The role of the laboratory in treatment with new oral anticoagulants,” Journal of Thrombosis and Haemostasis, vol. 11, supplement 1, pp. 122–128, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. D. Garcia, Y. C. Barrett, E. Ramacciotti, and J. I. Weitz, “Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants,” Journal of Thrombosis and Haemostasis, vol. 11, no. 2, pp. 245–252, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. J. Douxfils, F. Mullier, C. Loosen, C. Chatelain, B. Chatelain, and J.-M. Dogné, “Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature,” Thrombosis Research, vol. 130, no. 6, pp. 956–966, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. Y. Morishima and C. Kamisato, “Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay,” American Journal of Clinical Pathology, vol. 143, no. 2, pp. 241–247, 2015. View at Publisher · View at Google Scholar · View at Scopus
  63. E. S. Eerenberg, P. W. Kamphuisen, M. K. Sijpkens, J. C. Meijers, H. R. Buller, and M. Levi, “Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects,” Circulation, vol. 124, no. 14, pp. 1573–1579, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. R. Herrmann, J. Thom, A. Wood, M. Phillips, S. Muhammad, and R. Baker, “Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban,” Thrombosis and Haemostasis, vol. 111, no. 5, pp. 989–995, 2014. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Tripodi, L. Padovan, C. Veena, E. Scalambrino, S. Testa, and F. Peyvandi, “How the direct oral anticoagulant apixaban affects thrombin generation parameters,” Thrombosis Research, vol. 135, no. 6, pp. 1186–1190, 2015. View at Publisher · View at Google Scholar · View at Scopus
  66. H. Zahir, K. S. Brown, A. G. Vandell et al., “Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate,” Circulation, vol. 131, no. 1, pp. 82–90, 2015. View at Publisher · View at Google Scholar · View at Scopus
  67. L. M. Asmis, L. Alberio, A. Angelillo-Scherrer et al., “Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 swiss laboratories,” Thrombosis Research, vol. 129, no. 4, pp. 492–498, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. Y. C. Barrett, Z. Wang, C. Frost, and A. Shenker, “Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay,” Thrombosis and Haemostasis, vol. 104, no. 6, pp. 1263–1271, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Cuker and H. Husseinzadeh, “Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review,” Journal of Thrombosis and Thrombolysis, vol. 39, no. 3, pp. 288–294, 2015. View at Publisher · View at Google Scholar · View at Scopus
  70. D. M. Adcock and R. Gosselin, “Direct oral anticoagulants (DOACs) in the laboratory: 2015 review,” Thrombosis Research, vol. 136, no. 1, pp. 7–12, 2015. View at Publisher · View at Google Scholar · View at Scopus
  71. J. H. Levy, W. Ageno, N. C. Chan, M. Crowther, P. Verhamme, and J. I. Weitz, “When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH,” Journal of Thrombosis and Haemostasis, vol. 14, no. 3, pp. 623–627, 2016. View at Publisher · View at Google Scholar
  72. M. Makris, J. J. Van Veen, C. R. Tait, A. D. Mumford, and M. Laffan, “Guideline on the management of bleeding in patients on antithrombotic agents,” British Journal of Haematology, vol. 160, no. 1, pp. 35–46, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. D. A. Garcia and M. A. Crowther, “Reversal of warfarin: case-based practice recommendations,” Circulation, vol. 125, no. 23, pp. 2944–2947, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. R. I. Baker, P. B. Coughlin, A. S. Gallus, P. L. Harper, H. H. Salem, and E. M. Wood, “Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis,” The Medical Journal of Australia, vol. 181, no. 9, pp. 492–497, 2004. View at Google Scholar
  75. M. Makris and H. G. Watson, “The management of coumarin-induced over-anticoagulation Annotation,” British Journal of Haematology, vol. 114, no. 2, pp. 271–280, 2001. View at Publisher · View at Google Scholar
  76. D. F. O'Shaughnessy, C. Atterbury, P. Bolton Maggs et al., “Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant,” British Journal of Haematology, vol. 126, no. 1, pp. 11–28, 2004. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Zareh, A. Davis, and S. Henderson, “Reversal of warfarin-induced hemorrhage in the emergency department,” Western Journal of Emergency Medicine, vol. 12, no. 4, pp. 386–392, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Pandey and G. N. Vyas, “Adverse effects of plasma transfusion,” Transfusion, vol. 52, supplement 1, pp. 65S–79S, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. M. Makris, M. Greaves, W. S. Phillips, S. Kitchen, F. R. Rosendaal, and F. E. Preston, “Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy,” Thrombosis and Haemostasis, vol. 77, no. 3, pp. 477–480, 1997. View at Google Scholar · View at Scopus
  80. S. Schulman and N. R. Bijsterveld, “Anticoagulants and their reversal,” Transfusion Medicine Reviews, vol. 21, no. 1, pp. 37–48, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. KCENTRA, CSL Behring, King of Prussia, Pa, USA, 2013, http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-bio-gen/documents/document/ucm350239.pdf.
  82. R. Sarode, T. J. Milling, M. A. Refaai et al., “Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase iiib study,” Circulation, vol. 128, no. 11, pp. 1234–1243, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. A. Majeed, H.-G. Hwang, S. J. Connolly et al., “Management and outcomes of major bleeding during treatment with dabigatran or warfarin,” Circulation, vol. 128, no. 21, pp. 2325–2332, 2013. View at Publisher · View at Google Scholar · View at Scopus
  84. C. Held, E. M. Hylek, J. H. Alexander et al., “Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial,” European Heart Journal, vol. 36, no. 20, pp. 1264–1272, 2015. View at Publisher · View at Google Scholar · View at Scopus
  85. J. P. Piccini, J. Garg, M. R. Patel et al., “Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial,” European Heart Journal, vol. 35, no. 28, pp. 1873–1880, 2014. View at Publisher · View at Google Scholar · View at Scopus
  86. J. Skaistis and T. Tagami, “Risk of fatal bleeding in episodes of major bleeding with new oral anticoagulants and vitamin k antagonists: a systematic review and meta-analysis,” PLoS ONE, vol. 10, no. 9, Article ID e0137444, 2015. View at Publisher · View at Google Scholar
  87. C. T. January, L. S. Wann, J. S. Alpert et al., “2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society,” Journal of the American College of Cardiology, vol. 64, no. 21, pp. e1–e76, 2014. View at Publisher · View at Google Scholar · View at Scopus
  88. D. Faraoni, J. H. Levy, P. Albaladejo, and C. Samama, “Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants,” Critical Care, vol. 19, article 203, 2015. View at Publisher · View at Google Scholar
  89. G. Breuer, D. R. Weiss, and J. Ringwald, “‘New’ direct oral anticoagulants in the perioperative setting,” Current Opinion in Anaesthesiology, vol. 27, no. 4, pp. 409–419, 2014. View at Publisher · View at Google Scholar · View at Scopus
  90. R. Ferrandis, J. Castillo, J. de Andrés et al., “The perioperative management of new direct oral anticoagulants: a question without answers,” Thrombosis and Haemostasis, vol. 110, no. 3, pp. 515–522, 2013. View at Publisher · View at Google Scholar · View at Scopus
  91. W. I. Gonsalves, R. K. Pruthi, and M. M. Patnaik, “The new oral anticoagulants in clinical practice,” Mayo Clinic Proceedings, vol. 88, no. 5, pp. 495–511, 2013. View at Publisher · View at Google Scholar · View at Scopus
  92. K. Ogata, J. Mendell-Harary, M. Tachibana et al., “Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers,” Journal of Clinical Pharmacology, vol. 50, no. 7, pp. 743–753, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. D. A. Parasrampuria, T. Marbury, N. Matsushima et al., “Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis,” Thrombosis and Haemostasis, vol. 113, no. 4, pp. 719–727, 2015. View at Publisher · View at Google Scholar
  94. J. van Ryn, J. Stangier, S. Haertter et al., “Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity,” Thrombosis and Haemostasis, vol. 103, no. 6, pp. 1116–1127, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. M. Levi, K. T. Moore, C. F. Castillejos et al., “Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers,” Journal of Thrombosis and Haemostasis, vol. 12, no. 9, pp. 1428–1436, 2014. View at Publisher · View at Google Scholar · View at Scopus
  96. R. Marlu, E. Hodaj, A. Paris, P. Albaladejo, J. L. Crackowski, and G. Pernod, “Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers,” Thrombosis and Haemostasis, vol. 108, no. 2, pp. 217–224, 2012. View at Publisher · View at Google Scholar · View at Scopus
  97. G. Escolar, V. Fernandez-Gallego, E. Arellano-Rodrigo et al., “Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood,” PLoS ONE, vol. 8, no. 11, Article ID e78696, 2013. View at Publisher · View at Google Scholar · View at Scopus
  98. T. Fukuda, Y. Honda, C. Kamisato, Y. Morishima, and T. Shibano, “Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents,” Thrombosis and Haemostasis, vol. 107, no. 2, pp. 253–259, 2012. View at Publisher · View at Google Scholar · View at Scopus
  99. FEIBA, Baxter Healthcare Corporation, Westlake Village, Calif, USA, 2013, http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM221749.pdf.
  100. R. Alikhan, R. Rayment, D. Keeling et al., “The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran,” Emergency Medicine Journal, vol. 31, no. 2, pp. 163–168, 2014. View at Publisher · View at Google Scholar · View at Scopus
  101. H. Shakur, I. Roberts, R. Bautista et al., “Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial,” The Lancet, vol. 376, no. 9734, pp. 23–32, 2010. View at Publisher · View at Google Scholar
  102. A. Clavé, F. Fazilleau, D. Dumser, and J. Lacroix, “Efficacy of tranexamic acid on blood loss after primary cementless total hip replacement with rivaroxaban thromboprophylaxis: a case-control study in 70 patients,” Orthopaedics and Traumatology: Surgery and Research, vol. 98, no. 5, pp. 484–490, 2012. View at Publisher · View at Google Scholar · View at Scopus
  103. C. V. Pollack Jr., P. A. Reilly, J. Eikelboom et al., “Idarucizumab for dabigatran reversal,” The New England Journal of Medicine, vol. 373, pp. 511–520, 2015. View at Publisher · View at Google Scholar
  104. S. Hollenbach, G. Lu, F. DeGuzman et al., “Abstract 14657: andexanet-alfa and PER977 (Arapazine) correct blood loss in a rabbit liver laceration model—only andexanet reverses markers of fXa-mediated anticoagulation,” Circulation, vol. 130, abstract A14657, 2014. View at Google Scholar
  105. A. Gómez-Outes, M. L. Suárez-Gea, R. Lecumberri, A. I. Terleira-Fernández, and E. Vargas-Castrillón, “Specific antidotes in development for reversal of novel anticoagulants: a review,” Recent Patents on Cardiovascular Drug Discovery, vol. 9, no. 1, pp. 2–10, 2014. View at Publisher · View at Google Scholar · View at Scopus
  106. J. E. Ansell, S. H. Bakhru, B. E. Laulicht et al., “Use of PER977 to reverse the anticoagulant effect of edoxaban,” The New England Journal of Medicine, vol. 371, no. 22, pp. 2141–2142, 2014. View at Publisher · View at Google Scholar · View at Scopus
  107. G. Lu, F. R. DeGuzman, S. J. Hollenbach et al., “A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa,” Nature Medicine, vol. 19, no. 4, pp. 446–451, 2013. View at Publisher · View at Google Scholar · View at Scopus
  108. D. M. Siegal and A. Cuker, “Reversal of target-specific oral anticoagulants,” Drug Discovery Today, vol. 19, no. 9, pp. 1465–1470, 2014. View at Publisher · View at Google Scholar · View at Scopus
  109. A. M. Gold, M. Crowther, G. Levy et al., “ANNEXA-R: a phase 3 randomized, double-blind, placebo-controlled trial, demonstrating reversal of rivaroxaban-induced anticoagulation in older subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors,” Journal of the American College of Cardiology, vol. 65, no. 10, article A23, 2015. View at Publisher · View at Google Scholar
  110. M. Crowther, G. G. Levy, G. Lu et al., “ANNEXA-A: a phase 3 randomized, double-blind, placebo-controlled trial, demonstrating reversal of apixaban-induced anticoagulation in older subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors,” in Proceedings of the American Heart Association Scientific Sessions “Clinical Science: Special Reports”, Chicago, Ill, USA, November 2014.
  111. M. Franchini and G. Lippi, “Prothrombin complex concentrates: an update,” Blood Transfusion, vol. 8, no. 3, pp. 149–154, 2010. View at Publisher · View at Google Scholar · View at Scopus
  112. A.-C. Martin, B. Le Bonniec, A.-M. Fischer et al., “Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis,” International Journal of Cardiology, vol. 168, no. 4, pp. 4228–4233, 2013. View at Publisher · View at Google Scholar · View at Scopus
  113. J. Biskupiak, S. R. Ghate, T. Jiao, and D. Brixner, “Cost implications of formulary decisions on oral anticoagulants in nonvalvular atrial fibrillation,” Journal of Managed Care Pharmacy, vol. 19, no. 9, pp. 789–798, 2013. View at Publisher · View at Google Scholar · View at Scopus
  114. M. F. Bullano, V. Willey, O. Hauch, G. Wygant, A. C. Spyropoulos, and L. Hoffman, “Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization,” Journal of Managed Care Pharmacy, vol. 11, no. 8, pp. 663–673, 2005. View at Publisher · View at Google Scholar · View at Scopus
  115. A. Amin, A. Bruno, J. Trocio, J. Lin, and M. Lingohr-Smith, “Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US,” Journal of Medical Economics, vol. 18, no. 6, pp. 399–409, 2015. View at Publisher · View at Google Scholar · View at Scopus
  116. S. M. Singh and H. C. Wijeysundera, “Cost-effectiveness of novel oral anticoagulants for stroke prevention in non-valvular atrial fibrillation,” Current Cardiology Reports, vol. 17, article 61, 2015. View at Publisher · View at Google Scholar · View at Scopus
  117. A. Maan, E. K. Heist, J. N. Ruskin, and M. Mansour, “Practical issues in the management of novel oral anticoagulants-cardioversion and ablation,” Journal of Thoracic Disease, vol. 7, no. 2, pp. 115–131, 2015. View at Publisher · View at Google Scholar · View at Scopus
  118. F. Lozano, J. Trujillo-Santos, M. Barrón et al., “Home versus in-hospital treatment of outpatients with acute deep venous thrombosis of the lower limbs,” Journal of Vascular Surgery, vol. 59, no. 5, pp. 1362.e1–1367.e1, 2014. View at Publisher · View at Google Scholar · View at Scopus
  119. D. Aujesky, P.-M. Roy, F. Verschuren et al., “Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial,” The Lancet, vol. 378, no. 9785, pp. 41–48, 2011. View at Publisher · View at Google Scholar · View at Scopus
  120. D. M. Beam, Z. P. Kahler, and J. A. Kline, “Immediate discharge and home treatment with rivaroxaban of low-risk venous thromboembolism diagnosed in two U.S. emergency departments: a one-year preplanned analysis,” Academic Emergency Medicine, vol. 22, no. 7, pp. 788–795, 2015. View at Publisher · View at Google Scholar · View at Scopus
  121. I. M. van Korlaar, C. Y. Vossen, F. R. Rosendaal et al., “The impact of venous thrombosis on quality of life,” Thrombosis Research, vol. 114, no. 1, pp. 11–18, 2004. View at Publisher · View at Google Scholar · View at Scopus
  122. C. L. Marvig, T. I. Verhoef, A. de Boer et al., “Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants,” Thrombosis Research, vol. 136, no. 1, pp. 69–75, 2015. View at Publisher · View at Google Scholar · View at Scopus
  123. B. U. Monz, S. J. Connolly, M. Korhonen, H. Noack, and J. Pooley, “Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study,” International Journal of Cardiology, vol. 168, no. 3, pp. 2540–2547, 2013. View at Publisher · View at Google Scholar · View at Scopus